Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
— Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy ofZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant Crohn's disease (CD) — Findings support the therapeutic potential ofZYMFENTRA in addressing persistent treatment gaps especially in ileum-dominant CD Celltrion, Inc. today announced that a post-hoc analysis of the LIBERTY-CD study, which […]